In this interview, CEO Martin Gouldstone of Oncimmune #ONC - a leading life sciences firm offering autoantibody profiling services to the Biopharma & CROs industries – takes me through :
00:00 What the company does and the future growth in precision medicine
07:20 New application area in human longevity/ageing
10:25 Current client demand
12:00 Update on ONC’s commercialisation/turnaround strategy
13:25 Outlook & goals for FY25
16:15 Cash runway ahead
